100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mut... von Tedeschi, A., Peng, D.H., Schischlik-Siegl, F., Schaaf, O., Gerlach, D., Rocchetti, F., Popow, J., Broeker, J., Wunberg, T., Boghossian, A.S., Rees, M.G., Ronan, M.M., Roth, J.A., Williams, M., Vellano, C., Marszalek, J.R., Heffernan, T.P., Pearson, M., Kraut, N., Dorothea, R.

Volltext